 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News Vertex HIV Drug Candidate Development Halted by GlaxoSmithKline Because of Formulation ProblemDecember 22, 2006 GlaxoSmithKline has stopped collaborating with Vertex Pharmaceuticals Inc. on the HIV drug candidate brecanavir (VX-385), Vertex said in a recent Securities and Exchange Commission filing. The drug, which was in mid-stage clinical testing, would be too difficult to formulate, said Glaxo. The firms have collaborated since 1993, yielding the HIV treatments Agenerase and Lexiva. Associated Press 12.18.2006  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
